Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
=== Supply Chain Magazines === In September 2022, ISCEA Indonesia released Supply Chain Insights, a virtual magazine intended to share information and knowledge among Indonesian supply chain professionals. In April 2024, the Global "Sustainable Supply Chain" Magazine was released with Ushasi Segupta as Editor in Chief and Madison DeSilva as Publisher. In 2025, Dr. Mahmoud Mansi, an award-winning author of 9 books and Advisory Board Member at ISCEA, was appointed Editor in Chief of ISCEA's "Supply Chain Journal Middle East".
=== Scams === In the early 2000s, numerous companies advertised açaí products online, with many ads featuring counterfeit testimonials and products. In 2009, açaí scams were ranked No. 1 on the U.S. Federal Trade Commission's "scams and rip-offs" list, so that by 2011 sales of açaí flattened as the fad waned. According to the Washington, D.C.–based Center for Science in the Public Interest thousands of consumers had trouble stopping recurrent charges on their credit cards when they canceled free trials of some açai-based products. In 2003, American celebrity doctor Nicholas Perricone included açaí berries among "superfoods", but such extravagant marketing claims regarding açaí as miracle cures for everything from obesity to attention-deficit disorder were challenged in subsequent studies. The FTC handed down an $80 million judgement in January 2012 against five companies that were marketing açaí berry supplements with fraudulent claims that their products promoted weight loss and prevented colon cancer. One company, Central Coast Nutraceuticals, was ordered to pay a $1.5 million settlement.
Other viruses have been implicated in its etiology, including cytomegalovirus, rubella virus, rotavirus, mumps virus, and SARS-CoV-2. Maternal infection during pregnancy has been associated with the development type 1 diabetes in the offspring; these studies implicated maternal infections with enteroviruses, cytomegalovirus and rubella virus.
==== Hermaphroditism ==== Some teleost species are hermaphroditic, which can come in two forms: simultaneous and sequential. In the former, both spermatozoa and eggs are present in the gonads. Simultaneous hermaphroditism typically occurs in species that live in the ocean depths, where potential mates are sparsely dispersed. Self-fertilisation is rare and has only been recorded in two species, Kryptolebias marmoratus and Kryptolebias hermaphroditus. With sequential hermaphroditism, individuals may function as one sex early in their adult life and switch later in life. Species with this condition include parrotfish, wrasses, sea basses, flatheads, sea breams and lightfishes. Protandry is when an individual starts out male and becomes female while the reverse condition is known as protogyny, the latter being more common. Changing sex can occur in various contexts. In the bluestreak cleaner wrasse, where males have harems of up to ten females, if the male is removed the largest and most dominant female develops male-like behaviour and eventually testes. If she is removed, the next ranking female takes her place. In the species Anthias squamipinnis, where individuals gather into large groups and females greatly outnumber males, if a certain number of males are removed from a group, the same number of females change sex and replace them. In clownfish, individuals live in groups and only the two largest in a group breed: the largest female and the largest male. If the female dies, the male switches sexes and the next largest male takes his place.
Sources: en.wikipedia.org
== Etymology == The name Malaysia is a combination of the word Malays and the Latin-Greek suffix -ia/-ία, which can be translated as 'land of the Malays'. Similar-sounding variants have also appeared in accounts older than the 11th century, as toponyms for areas in Sumatra or referring to a larger region around the Strait of Malacca. The Sanskrit text Vayu Purana, thought to have been in existence since the first millennium CE, mentioned a land named 'Malayadvipa', which was identified by certain scholars as the modern Malay Peninsula. Other notable accounts are by Ptolemy's 2nd-century Geographia, which used the name Malayu Kulon for the west coast of Golden Chersonese, and the 7th-century Yijing's account of Malayu. At some point, the Melayu Kingdom took its name from the Sungai Melayu. Melayu then became associated with Srivijaya, and remained associated with various parts of Sumatra, especially Palembang, where the founder of the Malacca Sultanate is thought to have come from. It is only thought to have developed into an ethnonym as Malacca became a regional power in the 15th century. Islamisation established an ethnoreligious identity in Malacca, with the term Melayu beginning to appear as interchangeable with Melakans. It may have specifically referred to local Malay speakers who were loyal to the Malaccan Sultan. The initial Portuguese use of Malayos reflected this, referring only to the ruling people of Malacca.
Margot lived at the foot of Canyon Mountain, right outside of Livingston. Like much of Montana, the mountain was filled with wolves. But instead of fearing them, Margot loved them. She left meat out for the wolves so she could watch them come down the mountain and eat from the safety of her home ... She'd asked her closest friends—if they stopped by her place and found her dead—to tell no one, place her naked body in a bedsheet, drag it up Canyon Mountain, and leave her for her other friends, the wolves. Kidder's body was cremated, and the ashes were scattered by her brother John in her favorite childhood locations in Canada, as well as in Montana, amongst lilies which were frequently eaten by grizzly bears, partially fulfilling Kidder's wish to "have her body just left out there for the bears."
As of late 2007, two structures have been solved for this class of enzymes, with PDB accession codes PDB: 1Q7L and PDB: 1YSJ. These structures also correspond to two known primary amino acid sequences for aminoacylases. The associated papers identify two types of domains comprising aminoacylases: Zinc binding domains - which bind Zn2+ ions - and domains that facilitate dimerization of Zinc binding domains. It is this dimerization that allows catalysis to occur, since aminoacylase's active site lies between its two Zinc binding domains. Bound Zinc facilitates the binding of the N-acyl-L-amino acid substrate, causing a conformational shift that brings the protein's subunits together around the substrate and allowing catalysis to occur. Aminoacylase 1 exists in a heterotetrameric structure, meaning 2 Zinc binding domains and 2 dimerization domains come together to make aminoacylase 1's quaternary structure.
Adhesion G protein-coupled receptor G1 also known as GPR56 is a protein encoded by the ADGRG1 gene. ADGRG1 is a member of the adhesion GPCR family. Adhesion GPCRs are characterized by an extended extracellular region often possessing N-terminal protein modules that is linked to a TM7 region via a domain known as the GPCR-Autoproteolysis INducing (GAIN) domain. ADGRG1 is expressed in liver, muscle, tendon, neural, and cytotoxic lymphoid cells in human as well as in hematopoietic precursor, muscle, and developing neural cells in the mouse. ADGRG1 has been shown to have numerous role in cell guidance/adhesion as exemplified by its roles in tumour inhibition and neuron development. More recently it has been shown to be a marker for cytotoxic T cells and a subgroup of Natural killer cells. The ADGRG1 protein binds transglutaminase 2 to suppress tumor metastasis and binds collagen III to regulate cortical development and lamination.
The NAD-I riboswitch (also called the nadA motif) was identified in species of the bacterial phylum Acidobacteriota, where it typically resides upstream of nadA genes encoding quinolate synthase, an enzyme in the de novo NAD⁺ biosynthesis pathway. Unusually, despite regulating genes relevant to NAD⁺ metabolism, neither binding domain of the NAD⁺-I riboswitch's dual-aptamer architecture has been shown to specifically recognize the nicotinamide portion of the coenzyme; instead, the RNA robustly binds the adenosine 5′-diphosphate (ADP) moiety of NAD⁺.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.